Page 5 - Lymphoma Program News Today

/PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) recognized and celebrated the outstanding contributions of six LLS-funded scientific investigators for...

RYE BROOK, N.Y., Dec. 14, 2022 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) recognized and celebrated the outstanding contributions of si...

A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy reg...

Buffalo, NY, and Atlanta, GA (PRWEB) November 02, 2022 -- BUFFALO, N.Y., and ATLANTA, Ga. — A targeted therapy for children with high-risk Hodgkin lymphoma

/PRNewswire/ -- The global leader in the fight against blood cancers, The Leukemia & Lymphoma Society (LLS), announced the launch of its Pediatric Acute...

68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah

Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1...

68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1...

68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable saf...